1. Scrip
  2. >>Focus On Asia
  3. >>China

When Curtain Falls: 4+7 To 4+N Signals End To Branded Generics In China?

 
• By Brian Yang

After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.

Shanghai
EXPANSION OF SHANGHAI-INITIATED '4+7' SCHEME TO BRING PRICE PRESSURE ON BRANDED GENERICS • Source: Shutterstock

The off-patent product business of branded generics has had a long winning streak in China, sustaining years of double-digit growth for companies and driven by some well-established brands. Even when market shares in the US and Europe have eroded greatly, the same products have continued to enjoy healthy growth in China.

But this so-called “long tail” now seems to be near its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia